Abstract:Anti-tumour necrosis factor-α (TNF-α) therapy brought new hopes for treating rheumatic diseases but also increased the risk of infection, including mycobacterium tuberculosis (MTb). Conventional screening tools, such as tuberculin skin test (TST), lack sensitivity or specificity. Recently, T-SPOT.TB has been introduced to detect tuberculosis infection. Reports have proved its superior performance in detecting tuberculosis infection in various patient populations than the TST. To compare the value of a T-cell-based enzyme-linked immunospot assay (ELISPOT) T-SPOT.TB and conventional (TST) in screening and monitoring tuberculosis in patients with rheumatic diseases during infliximab therapy in China. Fifty-eight patients with various rheumatic diseases who received infliximab therapy were enrolled in the trial. Freshly isolated peripheral blood mononuclear cells were stimulated with MTb-specific antigens (ESAT-6 and CFP10), and IFN-γ-producing cells were counted. TST was performed with 1 TU PPD injected intradermally into the volar aspect of forearm. A cutaneous induration with diameter ≥5 mm was considered as positive TST, and an increment ≥5 mm of cutaneous induration was considered as TST conversion. TST and T-SPOT.TB test were carried out at baseline and repeated 12 months after infliximab therapy (if no active TB occurs) or at times when TB occurred. Moreover, all patients were initially evaluated for latent tuberculosis infection (LTBI) with clinical examination and chest radiograph. The McNemar test was used for TST and T-SPOT.TB concordance analysis. Cohen’s kappa coefficient was used to assess strength of the agreement. Among the 58 patients evaluated, 25 (43.1%) had ankylosing spondylitis, 24 (41.4%) had rheumatoid arthritis, 4 (6.9%) had undifferentiated spondyloarthropathy, 3 (5.2%) had psoriatic arthritis and 2 (3.4%) had reactive arthritis. A total of 52 patients (89.7%) had previously received vaccination with Bacille Calmette-Guerin. All of the patients received either single or combination of disease modifying anti-rheumatic drug (DMARDs) therapy, and 16 (27.4%) had previously or presently received glucocorticoid therapy. Before infliximab therapy, 12 patients (20.7%) had positive and 46 (79.3%) had negative TST results, and only 1 (1.7%) had positive T-SPOT.TB. Among 51 patients completing the repeated TST and T-SPOT.TB assay, 7 patients (13.7%) had TST conversion and 4 (7.8%) had positive T-SPOT.TB results. Of 7 patients with TST conversion, 2 patients (28.6%) developed active TB and also had positive T-SPOT.TB results; of 44 patients with no TST conversion, 2 patients (4.5%) had positive T-SPOT.TB and 1 (2.3%) had active TB. If 5 mm was used as the cut-off value of TST, TST and T-SPOT.TB, had an agreement value of 68.6% with a kappa value of 0.166. If 10 mm was used as the cut-off value, the agreement between TST and T-SPOT.TB was 88.2% with a kappa value of 0.338. T-SPOT.TB was more specific than TST in detecting tuberculosis during infliximab therapy in China with high BCG vaccination and high prevalence of TB. It can be used as a reliable tool for TB monitoring during infliximab therapy in Chinese patients with rheumatic diseases. Finally, it is recommended to repeat the TST and T-SPOT.TB periodically during biological treatment.

Interferon-gamma ELISPOT for the Screening and Diagnosis of Latent Tuberculosis Infection in Healthy Population of China

The Diagnostic Efficiency Evaluation of Combination Tuberculosis Interferon-Gamma Release Assay with Human Leukocyte Antigen-G for Tuberculosis

Comparison of an in-house tuberculosis-specific IFN-γ release assays with T-SPOT TB in latent tuberculosis infection diagnosis among HIV-infected individuals

Investigation of the Latent Mycobacterium Tuberculosis Infections in Different Populations in Shenzhen Area Using a Tuberculosis Antigen-Specific IFN-γ Elispot Assay.

Diagnostic Performance of Interferon-Gamma Releasing Assay in HIV-infected Patients in China.

High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-γ release assay among HIV-infected individuals in BCG-vaccinated area

Interferon-γ Release Assays Screening for Latent Tuberculosis Screening: A Cost-Effectiveness Analysis

Evaluation of enzyme-linked immunospot assay detecting Mycobacterium tuberculosis specific T cell responses in patients with pulmonary tuberculosis

Characterization of cytokine profile to distinguish latent tuberculosis from active tuberculosis and healthy controls.

Screening of tuberculosis infection in household contacts by interferon γ release assay and tuberculin skin test to predict active tuberculosis in China

Clinical Application of T-SPOT.TB in Diagnosis of HIV/AIDS and TB Patients

Clinical Application and Antigenicity of ESAT-6/CFP-10 Fusion Protein in Diagnosis of Tuberculosis

Evaluation of Gamma Interferon Release Assays Using Mycobacterium Tuberculosis Antigens for Diagnosis of Latent and Active Tuberculosis in Mycobacterium Bovis Bcg-Vaccinated Populations

Evaluation of the Diagnostic Potential of IP-10 and IL-2 As Biomarkers for the Diagnosis of Active and Latent Tuberculosis in a BCG-Vaccinated Population

Diagnosis of Latent Tuberculosis by ELISPOT Assay and Tuberculin Skin Test

Evaluation of the Characteristics of the Enzyme-Linked Immunospot Assay for Diagnosis of Active Tuberculosis in China

A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy

Development And Evaluation Of A New Interferon-Gamma Release Assay For The Diagnosis Of Tuberculosis Infection In Hiv-Infected Individuals In China

Comparison of two interferon-gamma release assays in the diagnosis of tuberculosis]

Evaluation Of Interferon-Gamma Release Assay (T-Spot.Tb (Tm)) For Diagnosis Of Tuberculosis Infection In Rheumatic Disease Patients

Evaluation of interferon-gamma release technique in extra-pulmonary tuberculosis detection